Zelenetz [29] identified older age, low albumin, presence of hepatic dysfunction, bone marrow involvement by the disease and/or low neutrophil at diagnosis as predicting factors for high risk of neutropenia in the first cycle of chemotherapy and thereby potential risk for lower dose intensity. Here, ALB is linked to neutropenia.